American College of Physicians. Guidelines for counseling post-menopausal women about preventive hormone
therapy. Ann Intern Med.1992;117:1038-1041.
Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment
of the epidemiologic evidence. Prev Med.1991;20:47-63.
Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health.1998;19:35-72.
Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med.1999;340:1801-1811.
Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease
risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin
Intervention (PEPI) Trial. JAMA.1995;273:199-208.
Psaty BM, Heckbert SR, Atkins D.
et al. A review of the association of estrogens and progestins with cardiovascular
disease in post-menopausal women. Arch Intern Med.1993;153:1421-1427.
Sotaniemi EA, Kontturi MJ. Serum lipid levels and thromboembolic complications during estrogen
therapy of prostatic cancer. Scand J Urol Nephrol.1975;9:89-93.
Coronary Drug Project Research Group. The coronary drug project: initial findings leading to modifications
of its research protocol. JAMA.1970;214:1303-1313.
Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives:
a report to the committee on safety of drugs. BMJ.1970;2:203-209.
Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet.1996;348:977-980.
Grodstein F, Stampfer MJ, Goldhaber SZ.
et al. Prospective study of exogenous hormones and risk of pulmonary embolism
in women. Lancet.1996;348:983-987.
Hulley S, Grady D, Bush T.for the Heart and Estrogen/progestin Replacement Study (HERS) Research
Group. Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women. JAMA.1998;280:605-613.
Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who
are carriers of factor V Leiden mutation. Lancet.1994;344:1453-1457.
Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet.1999;353:1167-1173.
Rosendaal FR, Siscovick DS, Schwartz SM.
et al. Factor V Leiden (resistance to activated protein C) increases the risk
of myocardial infarction in young women. Blood.1997;89:2817-2821.
Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial
infarction in young women. Blood.1997;90:1747-1750.
Franco RF, Trip MD, ten Cate H.
et al. The 20210 G→A mutation in the 3′-untranslated region of
the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol.1999;104:50-54.
Arruda VR, Siquiera LH, Chiaparini LC.
et al. Prevalence of the prothrombin gene variant 20210 G→A among patients
with myocardial infarction. Cardiovasc Res.1998;37:42-45.
Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors:
increased risk of myocardial infarction associated with factor V Leiden or
prothrombin 20210A. Circulation.1998;97:1037-1041.
Cushman M, Rosendaal FR, Psaty BM.
et al. Factor V Leiden is not a risk factor for arterial vascular disease
in the elderly: results from the Cardiovascular Health Study. Thromb Haemost.1998;79:912-915.
Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction,
stroke, and venous thrombosis in a large cohort of US men. Circulation.1999;99:999-1004.
Redondo M, Watzke HH, Stucki B.
et al. Coagulation factors II, V, VII and X, prothrombin gene 20210G→A
transition, and factor V Leiden in coronary artery disease: high factor V
clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol.1999;19:1020-1025.
Gardemann A, Arsic T, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The factor II G20210A and factor V G1691A gene transitions and coronary
heart disease. Thromb Haemost.1999;81:208-213.
Psaty BM, Heckbert SR, Atkins D.
et al. The risk of myocardial infarction associated with the combined use
of estrogens and progestins in post-menopausal women. Arch Intern Med.1994;154:1333-1339.
Psaty BM, Heckbert SR, Koepsell TD.
et al. The risk of myocardial infarction associated with anti-hypertensive
drug therapies. JAMA.1995;274:620-625.
Psaty BM, Koepsell TD, LoGerfo JP, Wagner EH, Inui TS. β-Blockers and primary prevention of coronary heart disease in
patients with high blood pressure. JAMA.1989;261:2087-2094.
Psaty BM, Koepsell TD, Siscovick D.
et al. An approach to several problems in the use of large databases for population-based
case-control studies of the therapeutic efficacy and safety of anti-hypertensive
medicines. Stat Med.1991;10:653-662.
Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol.1993;22:1189-1192.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated
cells. Nucleic Acids Res.1988;16:1215.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the
prothrombin gene is associated with elevated plasma prothrombin levels and
an increase in venous thrombosis. Blood.1996;88:3698-3703.
Bertina RM, Koeleman BPC, Koster T.
et al. Mutation in blood coagulation factor V associated with resistance to
activated protein C. Nature.1994;369:64-67.
Schlesselman JJ. Case-Control Studies: Design, Conduct, Analysis. New York, NY: Oxford University Press; 1982.
Breslow NE, Day NE. Statistical Methods in Cancer Research: Volume 1—The
Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980.
IARC scientific publications No. 32.
Smith PG, Day NE. The design of case-control studies: the influence of confounding and
interaction effects. Int J Epidemiol.1984;13:356-365.
Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment
interaction: case-control studies with no controls. Am J Epidemiol.1996;144:207-213.
Yang Q, Khoury MJ, Flanders WD. Sample size requirements in case-only designs to detect gene-environment
interaction. Am J Epidemiol.1997;146:713-720.
Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism
in women aged 45-64 years: relationships to hormone replacement therapy. Thromb Haemost.2000;83:530-535.
Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE. Effect of exogenous estrogen on atherothrombotic vascular disease risk
related to the presence or absence of factor V Leiden (resistance to activated
protein C). Am J Cardiol.1999;84:549-554.
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic
regression analysis. J Clin Epidemiol.1996;49:1373-1379.
Barrett Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med.1991;115:455-456.
Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than
nonusers? Am J Epidemiol.1996;143:971-978.
Sechi LA, Zingaro L, Catena C, Casaccio D, Demarchi S. Relationship of fibrinogen levels and hemostatic abnormalities with
organ damage in hypertension. Hypertension.2000;36:978-985.
Lip GYH. Target organ damage and the prothrombotic state in hypertension. Hypertension.2000;36:975-977.